Skip to main content
News Thiele 01.2021
© AG Thiele / Uni Bonn

News categories: Publication

ImmunoSensation scientist discover differences in fat metabolism

The liver processes coconut oil differently than rapeseed oil

Coconut oil has increasingly found its way into German kitchens in recent years, although its alleged health benefits are controversial. Scientists at the University of Bonn from the Cluster of Excellence ImmunoSensation have now been able to show how it is metabolized in the liver. Their findings could also have implications for the treatment of certain diarrheal diseases. The results are published in the journal Molecular Metabolism.

Coconut oil differs from rapeseed or olive oil in the fatty acids it contains. Fatty acids consist of carbon atoms bonded together, usually 18 in number. In coconut oil, however, most of these chains are much shorter and contain only 8 to 12 carbon atoms. In the liver, these medium-chain fatty acids are partly converted into storage fats (triglycerides). Exactly how this happens was largely unknown until now. The new study now sheds light on this: "There are two enzymes in the liver for storage fat synthesis, DGAT1 and DGAT2," explains Dr. Klaus Wunderling of the LIMES Institute at the University of Bonn. "We have now seen in mouse liver cells that DGAT1 processes mainly medium-chain fatty acids and DGAT2 processes long-chain ones."

"The enzymes therefore seem to prefer different chain lengths," concludes Prof. Dr. Christoph Thiele of the LIMES Institute, who led the study and is also a member of the Cluster of Excellence Immunosensation. Surprising side effect whether fatty acids in the liver are used at all to build up storage fat depends on the current energy requirement. When the body needs a lot of energy at a particular moment, the so-called beta oxidation is fired up - the fatty acids are "burned" straight away, so to speak. Medically, this metabolic pathway is of great interest. In diabetes, for instance, it might be useful to reduce beta-oxidation.

Also interesting is a finding published a few years ago by Austrian and Dutch scientists: They had studied patients suffering from chronic diarrheal diseases. In 20 of them, they found alterations in the DGAT1 gene that rendered it nonfunctional. "We now want to find out whether the impaired processing of medium-chain fatty acids is responsible for the digestive complaints," says Wunderling. This is because the DGAT1 enzyme is active not only in the liver but also in the intestine. Perhaps this is why its disorder causes diarrhea when sufferers consume medium-chain fatty acids.


Funding

The study was funded by the German Research Foundation (DFG) as part of the Excellence Strategy. It additionally received funding from the Austrian Science Fund (FWF) of the Republic of Austria.


Publication

Klaus Wunderling, Christina Leopold, Isabell Jamitzky, Mohamed Yaghmour, Fabian Zink, Dagmar Kratky and Christoph Thiele: Hepatic synthesis of triacylglycerols containing medium-chain fatty acids is dominated by diacylglycerol acyltransferase 1 and efficiently inhibited by etomoxir; Molecular Metabolism; https://doi.org/10.1016/j.molmet.2020.101150


Contact

Dr. Klaus Wunderling

LIMES-Institut der Universität Bonn

Tel. 0228/ 7362820

E-mail: klausw@uni-bonn.de

Related news

Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

News categories: Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

News categories: Publication

A Ray of Hope in the Fight Against Cancer

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry
(from left) Julia Nicke and Dr. Mona Malek Mohammadi have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury.

News categories: Publication

Central Hub for Heart Repair Discovered Bonn study: Heart muscle interaction enables cardiac regeneration in the neonatal heart

Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury. The findings could open new avenues for future therapies aimed at repairing damaged adult hearts after heart attacks or chronic cardiovascular disease. The study has now been published in the journal Cell Communication and Signaling (Springer Nature).
View entry

Back to the news overview